Quest Diagnostics obtained rights to use and sell products and services incorporating
Nanogen’s MGB (minor groove binder) Probe technology. According to the end-user license agreement, Quest will pay an up-front fee and royalties on tests sold using this technology. Quest will be able to use this platform in human in vitro diagnostic testing.